For the most part, this issue pertains to small-molecule drugs rather than biologics. For these drugs, a slightly higher production cost in return for greater control over the supply chain seems like a reasonable tradeoff.
The problem will be where, exactly, in the US to locate the API factories, which make the organic intermediates that are the building blocks for small-molecule drugs. Nobody wants these kinds of facilities nearby.
Market Data 
Markets 
AI
